PRVB
Provention Bio Inc
Provention Bio Inc historical holders
total: 1
Fairfax Financial Holdings Provention Bio Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2023 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2023 Q2
Prem Watsa has been an institutional investor in Provention Bio Inc (PRVB) since 2023 Q1. According to 2026 Q1 report, Prem Watsa doesn't hold any shares. The fund/company first acquired PRVB in 2023 Q1, initially purchasing 277,000 shares. Since the initial investment, Fairfax Financial Holdings has made 1 more transaction in this position.
When did Prem Watsa exit their PRVB position?
Prem Watsa no longer holds Provention Bio Inc (PRVB). They sold off their entire position in 2023 Q2, closing out an investment that began in 2023 Q1.
When did Prem Watsa first invest in PRVB?
Prem Watsa first invested in Provention Bio Inc (PRVB) in 2023 Q1 at the reported quarter-end price of $24.09 per share, acquiring 277,000 shares in their initial purchase.
What is Prem Watsa's average cost basis for PRVB?
Based on historical transaction data, Prem Watsa's estimated cost basis for Provention Bio Inc (PRVB) is approximately $24.09 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $24.09
- Weighted AVG sell price:
- $24.09
PRVB transactions history by Fairfax Financial Holdings
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q2
|
0.00%
|
0
|
$24.09
|
|
-100% (-277,000)
|
-0.38%
|
|
2023 Q1
|
0.38%
|
277,000
|
$24.09
|
$6,672,930
|
new
|
+0.38%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.